



Contents lists available at BioMedSciDirect Publications

## International Journal of Biological & Medical Research

Journal homepage: [www.biomedscidirect.com](http://www.biomedscidirect.com)



### Original Article

# Renin- Angiotensin- Aldosterone System gene polymorphisms in Type 2 Diabetic patients among the Mewari population of Rajasthan.

Pulakes Purkait<sup>a</sup>, Prem Chand Suthar<sup>b</sup>; Vijay Kumar Purohit<sup>c</sup>; J. M. Naidu<sup>d</sup>; B.N. Sarkar<sup>e</sup>

<sup>a</sup>DNA laboratory unit, Anthropological Survey of India, WRC, Udaipur- 313001, Rajasthan, India

<sup>b</sup>Bhupalpura Govt. Dispensary, N road, Bhupalpura, Udaipur, Rajasthan, India

<sup>c</sup>Department of Anthropology, Andhra University, Visakhapatnam, Andhra Pradesh, India

<sup>d</sup>Anthropological Survey of India, 27 J.N. Road, Kolkata 700016, India

#### ARTICLE INFO

##### Keywords:

Diabetes

Mewari population

Polymorphism

RAAS

#### ABSTRACT

**Aim:** Diabetes is the one of the most serious health problems of modern times and India is the top most country with the highest number of individuals affected with type 2 diabetes and an extremely limited data on the genetics of diabetes in the Indian populations is available. In this context the aim of the present study was to investigate the distribution of RAAS pathway genes polymorphism and its relationship with Type 2 Diabetes patients in Mewari population. **Methods:** The present study examined the prevalence of RAAS gene polymorphism among 111 Mewari individuals from Udaipur, Rajasthan, India. Among them 50 individuals belong to type 2 diabetic (T2DM) and 61 healthy controls. Isolated DNA samples from the studied subjects were genotyped using PCR-RFLP methods. **Result:** There was a significant difference in age, gender, SBP, BMI, glucose, GGT, urea, creatinine, LDL and total protein between T2DM and Control subjects ( $p < 0.05$ ). The minor allele frequency of RAAS pathway gene polymorphism AGT (rs4762), REN (rs41317140), ACE (rs4646994), AGTR1 (rs5186), CYP11B2 (rs1799998) in T2DM patients (T2DM) are found to be 0.18, 0.20, 0.41, 0.05 and 0.30 respectively. The allele frequencies of the same polymorphisms among the normal controls are found to be 0.13, 0.16, 0.48, 0.10 and 0.40 respectively. The general associations were not found in significant result ( $p > 0.05$ ). **Conclusion:** The study found that no association of RAAS gene polymorphisms with increased risk of type 2 diabetes among the Mewari population except rs4762. The AGT (rs4762) was associated at recessive model ( $p = 0.038$ ).

© Copyright 2010 BioMedSciDirect Publications IJBM -ISSN: 0976:6685. All rights reserved.

### 1. Introduction

Diabetes is a common and complex metabolic disorder in modern time and caused by a combination of genes and environmental factors. Multiple genetic factors including those not underlying diabetes can contribute to the development of complications such as nephropathy, neuropathy, and retinopathy and most common complication of diabetes is hypertension. Hypertension increases with decreasing renal function [1] and is a risk factor for the development of ESRD [2-3]. This results from an activation of the renin-angiotensin-aldosterone system (RAAS) and the RAAS may [4] predispose to the development of renal failure and [5] promote a more rapid loss of glomerular filtration rate in

patients suffering from renal diseases. The renin -angiotensin system (RAS) plays major roles in blood pressure regulation and electrolyte metabolism [6] and pivotal roles in the pathophysiology of cardiovascular, renal, and metabolic conditions [7-8]. Genetic variants of this system have been developed to test their association with cardiovascular and renal conditions. Clinical evidence suggests that the renin- angiotensin-aldosterone system (RAAS) is associated with the etiology of type 2 diabetes [9 – 11]. Among the candidate genes of RAAS the Renin (REN), Angiotensinogen (AGT), Angiotensin- converting enzyme (ACE), Angiotensin II type1 receptor (AGT1R) and aldosterone synthase gene (CYP11B2) are of particular interest.

Therefore, the aim of the present study was to investigate the distribution of RAAS pathway genes polymorphism and its relationship with Type 2 Diabetes patients in Mewari population. In this work, we aimed at investigation the association of REN

\* Corresponding Author : Dr. B.N. Sarkar

Anthropological Survey of India,  
27 J.N. Road, Kolkata 700016, India  
Email: [diabetes.wrc@gmail.com](mailto:diabetes.wrc@gmail.com)

(rs41317140), AGT (rs4762), AGTR1 (rs5186), ACE (rs4646994), CYP11B2 (rs1799998) genetic markers and common anthropometric and clinical factors with type 2 diabetes among the Mewari population of Udaipur city of Rajasthan.

## 2. Materials and Methods

### 2.1. Subjects

The present study on RAAS pathway genes polymorphisms were carried out among 111 Mewari populations both sex, consisting of 50 Type 2 Diabetes patients (T2DM) and 61 healthy controls in and around Udaipur city of Rajasthan. Registered patients were recruited from Bhupalpura Govt. Dispensary, Udaipur and a detailed medical history of each patient was recorded accordingly. The detection of Type 2 diabetes was based on physician's recommendation. The healthy unrelated controls were randomly selected and recruited from local community centers. 10 ml of venous blood (6 ml was drawn into EDTA tube for genetic analyses and 4 ml was drawn into serum tube for biochemistry analysis) was collected from the participants by using sterilized disposable blood collection kits. Prior to the recruitment of subjects the ethical committee clearance was obtained from the respective medical institutions and accordingly informed consent was obtained from all the participants.

### 2.2. Anthropometric and Physical measurements

Anthropometric measurements and indices were taken in each subject, using standard methodology. Clinical data included information of duration of diabetes, presence of any complication, history of other disorders, systolic blood pressure, and diastolic blood pressure. Anthropometric data, weight (kg), and Height (cm), were obtained to calculate body mass index (BMI) using the formula, weight (kg)/ [height (m)<sup>2</sup>]. The blood pressure was measured on the right arm of the subjects using an automated blood pressure monitor (Omron, Japan) by seated and rested for 15 minutes. Blood glucose was measure using the Breez 2 glucometer (blood glucose monitor).

### 2.3. Biochemical analysis

4 ml of venous blood samples were drawn in the morning. Thereafter, the blood samples were centrifuged, serum were separated, collected and stored at -86°C until further analysis. All laboratory measurements were conducted at the DNA Laboratory in the Anthropological Survey of India, Western Regional Centre, Udaipur. The serum levels of GPT, GOT, GGT, Urea, Creatinine, Uric Acid, triglycerides(TG), total cholesterol, high-density lipoprotein cholesterol (HDL), low density lipoprotein cholesterol (LDL), Chloride, albumin and total Protein (TP) were measured enzymatically on a Fully auto analyzer EM360 (TRANSASIA with kits supplied by TRANSASIA BIO MEDICAL LTD).

### 2.4. Genotype assessment

Approximately 6 ml of venous blood was drawn from each of the subjects in EDTA vials and genomic DNA was extracted from whole fresh blood using standard salting out method using phenol-

chloroform [12]. Five polymorphisms from five genes namely ACE (I/D; rs4646994), AGT (T174M; rs4762), AGTR1 (A1166C; rs5186), CYP11B2 (T-344C; rs1799998), REN (C-4063 T; rs41317140) were chosen for genotyping using the polymerase chain reaction–restriction fragment length polymorphism (PCR-RFLP) analysis using the primers and details of which are presented in Table 1. All reaction were performed with 20 pmol of each primer in a final volume of 10µl containing 50ng of genomic DNA, 10X Taq PCR buffer, 25 mM MgCl<sub>2</sub>, 100 mM of each dNTPs and 1 U/uL of Taq polymerase. Electrophoreses of PCR products and digested PCR products were resolved on 2-3% agarose gel stained with ethidium bromide and directly visualized in UV light.

### 2.5. Statistical analysis

Data were analyzed using statistical package for Social Sciences statistical software (SPSS Version 16, Chicago, Illinois, USA). Data were presented as mean ± SD and comparison between T2DM and Control and among group were analyzed by the independent-sample T tests and one way ANOVA and cross tab analysis respectively.

Genotype and Allele frequencies were calculated for the SNPs and tested for Hardy-Weinberg equilibrium and allelic association with disease ( $\chi^2$ -test, exact tests, and Fisher- model tests) using PLINK (<http://pngu.mgh.harvard.edu/~purcell/plink/>) [18]. For comparing the allelic distributions between study groups the odds ratio (OR) with 95% confidence interval (CI) were also calculated. A level of P < 0.05 was assumed statistical significance.

## 3. Results

### 3.1. Baseline characteristics of the subjects

The anthropometric measurement and clinical characteristics of the subjects are presented in the Table 2. Significant differences were found between T2DM and Control SBP (p = 0.000), BMI (p = 0.043), glucose (p = 0.000), GGT (p = 0.022), urea (p = 0.001), creatinine (p = 0.000), LDL (p = 0.045), TP (p = 0.044), while the age, height, weight, DBP, GPT, GOT, uric acid, triglyceride, cholesterol, HDL, chloride and albumin did not reach statistical significance.

3.2. Primary information, distribution and different model tests of selected SNPs of the Renin - Angiotensin – Aldosterone system pathway genes

Primary information and allele frequencies of the selected SNPs of the renin - angiotensin – aldosterone system pathway genes are presented in Table 3. All the genotype distributions in these study groups were consistent with Hardy – Weinberg equilibrium expectation (p > 0.05). Allelic frequencies of all polymorphisms did not show any difference between T2DM and Control subjects of Mewari population of Udaipur city. The associations were further verified through different Fisher models test to confirm which of these 5 model best predict the associations at micro level (Table 4).

**Table 1: RAAS pathway genes SNPs, their location, primer sequence, PCR annealing temperature, product size and restriction enzyme with allele product sizes.**

| Gene & Polymorphism              | rsnumber   | Primer sequence  | Product Size (bp) | Annealing temp./ Restriction enzyme/ allele sizes     |
|----------------------------------|------------|--|-------------------|---|
| AGT<br>(Thr 174 Met)<br>[C3889T] | rs4762     | F: 5'-AGGCTGTACAGGGCCTGCTAGT-3'<br>R: 5'-GCCTTACCTTGGAAAGTGGACGTAG-3'<br>Ref: Nakajima T et al., 2002 [13] | 310               | Nco I<br>C = 310;<br>T = 64, 246                      |
| RENIN<br>(C-4063 T)              | rs41317140 | F: 5'-GCTGTCTTCTGGTGGTACTGCC-3'<br>R: 5'-TGCTGGCCATGAACTGGTTCTAGC-3'<br>Ref: Deinum J et al., 1999 [14]    | 964               | Taq I<br>T = 964 bp<br>C = 394, 570                   |
| ACE<br>(Ins/Del)                 | rs4646994  | F: 5'-CTGGAGACCACTCCCATCCTTTCT-3'<br>R: 5'-GATGTGGCCATCACATTCGTCAGAT-3'<br>Ref: Rigat B et al., 1992 [15]  | 490,190           | I = 490<br>D = 190                                    |
| AGTR1<br>(A 1166 C)              | rs5186     | F: 5'-AAGAAGCCTGCACCATGTTT-3'<br>R: 5'-CCATCTTACGGCATTGTTT-3'<br>Ref: Prasad P et al., 2006 [16]           | 626               | HpyF3I (DdeI)<br>A = 536, 90<br>C = 417, 119, 90      |
| CYP11B2<br>(T-344 C)             | rs1799998  | F: 5'-CAGGAGGAGACCCCATGTGAC-3'<br>R: 5'-CTCCACCCTGTTCAGCCAAAT-3'<br>Ref: Xiao J et al., 2007 [17]          | 536               | Hae III<br>C = 202, 138, 125, 71<br>T = 278, 138, 125 |

**Table 2: Anthropometric and Clinical Characteristics of the subjects**

| Variables                | Control (N = 61)<br>Mean ± SD | T2DM (N = 50)<br>Mean ± SD | P      |
|--------------------------|-------------------------------|----------------------------|--------|
| Age (Years)              | 53.26 ± 5.53                  | 55.70 ± 9.98               | 0.107  |
| SBP (mmHg)               | 123.16 ± 18.77                | 138.80 ± 21.37             | 0.000* |
| DBP (mmHg)               | 84.39 ± 8.78                  | 87.68 ± 11.22              | 0.086  |
| Height (cm)              | 164.19 ± 8.69                 | 162.27 ± 8.31              | 0.24   |
| Weight (kg)              | 164.19 ± 8.69                 | 162.27 ± 8.31              | 0.308  |
| BMI (kg/m <sup>2</sup> ) | 25.13 ± 3.13                  | 26.55 ± 4.14               | 0.043* |
| Glucose (mg/dl)          | 117.25 ± 20.37                | 184.66 ± 92.16             | 0.000* |
| GPT (U/L)                | 32.11 ± 17.39                 | 32.97 ± 22.05              | 0.819  |
| GOT (U/L)                | 23.55 ± 12.36                 | 25.00 ± 24.14              | 0.683  |
| GGT (U/L)                | 30.54 ± 19.89                 | 41.10 ± 27.92              | 0.022* |
| UREA (mg/dl)             | 17.00 ± 4.93                  | 23.46 ± 13.75              | 0.001* |
| Creatinine (mg/dl)       | 0.99 ± 0.14                   | 1.10 ± 0.19                | 0.000* |
| Uric Acid (mg/dl)        | 5.86 ± 1.35                   | 5.87 ± 1.56                | 0.966  |
| Triglyceride (mg/dl)     | 157.69 ± 72.33                | 182.52 ± 101.85            | 0.137  |
| Cholesterol (mg/dl)      | 162.31 ± 38.90                | 177.50 ± 48.52             | 0.07   |
| HDL (mg/dl)              | 41.40 ± 10.19                 | 43.79 ± 9.56               | 0.208  |
| LDL (mg/dl)              | 98.166 ± 24.79                | 109.21 ± 32.63             | 0.045* |
| Chloride (mmol/L)        | 101.00 ± 3.47                 | 100.60 ± 3.16              | 0.523  |
| Albumin (g/dl)           | 3.91 ± 0.24                   | 3.93 ± 0.27                | 0.682  |
| Total Protein (g/dl)     | 7.11 ± 0.53                   | 7.33 ± 0.58                | 0.044* |

\* Significant at the P&lt;0.05 level

**Table 3: Summary statistical analysis of RAAS genes by General association and HWE**

| CHR | rsnumber   | Genomic location | Minor allele | MAF of T2DM | MAF of CON | Major allele | X <sup>2</sup> | P value | OR     | 95% CI L | 95% CI U | HWE pvalue |
|-----|------------|------------------|--------------|-------------|------------|--------------|----------------|---------|--------|----------|----------|------------|
| 1   | rs4762     | 3889             | T            | 0.18        | 0.13       | C            | 1.011          | 0.3146  | 1.454  | 0.6991   | 3.025    | 0.2795     |
| 1   | rs41317140 | (T174M)-4063     | T            | 0.20        | 0.16       | C            | 0.7435         | 0.3886  | 1.355  | 0.6781   | 2.709    | 0.5174     |
| 17  | rs4646994  | Intron 16        | D            | 0.41        | 0.48       | I            | 0.9516         | 0.3293  | 0.7668 | 0.4496   | 1.308    | 0.8475     |
| 3   | rs5186     | 1166             | C            | 0.05        | 0.10       | A            | 1.818          | 0.1776  | 0.4825 | 0.164    | 1.419    | 1          |
| 8   | rs1799998  | -344             | C            | 0.30        | 0.40       | T            | 2.477          | 0.1155  | 0.6385 | 0.3646   | 1.118    | 0.413      |

(CHR= Chromosome, MAF = Minor allele frequency, \* Significant at the P <0.05 level)

**Table 4: Summary statistical analysis of RAAS pathway genes by Fisher - Model Tests**

| CHR | rs number  | Minor allele | Major allele | TEST    | T2DM    | CON      | P      |
|-----|------------|--------------|--------------|---------|---------|----------|--------|
| 1   | rs4762     | T            | C            | GENO    | 4/10/36 | 0/16/45  | 0.075  |
|     |            |              |              | TREND   | 18/82   | 16/106   | 0.337  |
|     |            |              |              | ALLELIC | 18/82   | 16/106   | 0.352  |
|     |            |              |              | DOM     | 14/36   | 16/45    | 0.834  |
|     |            |              |              | REC     | 4/46    | 0/61     | 0.038* |
| 1   | rs41317140 | T            | C            | GENO    | 2/16/32 | 0/19/42  | 0.335  |
|     |            |              |              | TREND   | 20/80   | 19/103   | 0.366  |
|     |            |              |              | ALLELIC | 20/80   | 19/103   | 0.479  |
|     |            |              |              | DOM     | 18/32   | 19/42    | 0.687  |
|     |            |              |              | REC     | 2/48    | 0/61     | 0.201  |
| 3   | rs5186     | C            | A            | GENO    | 0/5/45  | 0/12/49  | 0.192  |
|     |            |              |              | TREND   | 5/95    | 12/110   | 0.159  |
|     |            |              |              | ALLELIC | 5/95    | 12/110   | 0.211  |
|     |            |              |              | DOM     | 5/45    | 12/49    | 0.192  |
|     |            |              |              | REC     | 0/50    | 0/61     | 1      |
| 8   | rs1799998  | C            | T            | GENO    | 4/22/24 | 12/25/24 | 0.229  |
|     |            |              |              | TREND   | 30/70   | 49/73    | 0.129  |
|     |            |              |              | ALLELIC | 30/70   | 49/73    | 0.124  |
|     |            |              |              | DOM     | 26/24   | 37/24    | 0.442  |
|     |            |              |              | REC     | 4/46    | 12/49    | 0.106  |
| 17  | rs4646994  | D            | I            | GENO    | 9/23/18 | 12/34/15 | 0.421  |
|     |            |              |              | TREND   | 41/59   | 58/64    | 0.319  |
|     |            |              |              | ALLELIC | 41/59   | 58/64    | 0.345  |
|     |            |              |              | DOM     | 32/18   | 46/15    | 0.215  |
|     |            |              |              | REC     | 9/41    | 12/49    | 1      |

\* Significant at the P<0.05 level

**4. Discussion**

Diabetes is the one of the most serious health problems of modern times and India is the top most country with the highest number of individuals affected with type 2 diabetes. Regarding the epidemiological studies in India, an extremely limited data on the genetics of diabetes in the Indian populations is available. Numerous diabetes genetic studies that have been conducted in India thus far are population-based candidate gene association studies [16, 19-24].

In this report on RAAS pathway genes, we tested association of a total five polymorphism from promoter, exonic and intronic regions of five genes and 20 variables are tested for association between type 2 diabetic and controls in Mewari population.

The AGT T174M polymorphism is located at the exon 2 of the AGT gene on Chromosome 1. Genetic linkage study showed that AGT gene T174M and M235T variants were strongly associated with high blood pressure in diabetic patients [25]. In this study we observed a higher frequency of AGT 174 M (T) allele in the T2DM subjects (0.18) than in control subjects (0.13) in Mewari population. Estimated OR of T2DM with carrier M (T) allele as compared with control subjects was (1.454) with 95% CI (0.6991 – 3.025). We found T174 genotype frequency almost pattern to other populations and found no homozygous MM genotype in Control Subject like [26–29].

The Renin (– 4063 C >T) polymorphism is located at the promoter region of the gene. It has been shown that the frequency of the T allele is increased in T2DM subjects (0.20%) than control (0.16%) and estimated OR of T2DM with carrier T allele as compared with control subjects was 1.355 with 95% CI (0.678 – 2.709) and found no association with T2DM and rennin gene promoter polymorphism in Mewari population. Our study showed same result reported by Mtiraoui N et al. [30].

The ACE gene is located on chromosome 17q23 and the ACE gene polymorphism results from the insertion (I) or deletion (D) of a 287 bp Alu sequence near the 3' end of intron 16 (Rigat et al., 1992). In our study the frequency of the ACE deletion (D) allele has been found to be lower in T2DM patients (0.41) than control (0.48) subjects, found null association with T2DM and the result was totally different than the earlier reports [31–34]. At this stage we can presume that ACE gene can be used as a suitable marker for studying genetic variation among different human populations.

The AGTR1 gene A1166C polymorphism is located at the 5' end of the 3' UTR of the gene [35]. In our study showed that no association between the AGTR1 gene polymorphism and Mewari T2DM patients. It has been shown that the frequency of the AGTR1 C allele is increased in control (0.10) than T2DM patients (0.05).

The -344 (C >T; rs1799998) variant is a commonly reported polymorphism of the CYP11B2 gene, which is located at the promoter region [36]. The -344 (C >T) polymorphism is associated with serum aldosterone level and production [37–39], blood pressure [40–43]. Its association was reported with progression of renal function [44–46] and ESRD [47]. However, there were few studies from India have been found on the association of CYP11B2 -344C/T polymorphism and CRI [16], healthy volunteers [48]; hypertension [49–50]. In our study, The C allele frequency was the highest among Control subjects (0.40) than T2DM subject (0.30) and expected OR was 0.6385 with 95% CI (0.3646 – 1.118) but we could not observe significant differences in allele frequency ( $X^2 = 2.477$ ,  $p = 0.1155$ ) of the CYP11B2 gene (-344 T > C) polymorphism between T2DM patients and Controls subjects and the result follow our previous study [51].

## 5. Conclusion

This is the first report on genetics of type 2 diabetes among the Mewari population of Udaipur city, Rajasthan. On the whole it was observed through the analysis that there was no significant association at micro level also between REN, AGTR1, ACE and CYP11B2 gene polymorphism and T2DM in Mewari population. The AGT (T174M, rs4762) was statistically significant at micro level recessive model ( $p = 0.038$ ). This inconsistency result may be for our small sample size. Therefore while studying the susceptibility of RAAS gene with the etiology of type 2 diabetes we have to take care of the ethnic background of the population. Further studies and more samples size will definitely add more information to this issue.

## 6. Conflict of interest

The authors declare no conflict of interest for the present research outcome.

## 7. Acknowledgements

We would like to thank the members of the study populations and Dr. Lalit Kumar Gandharve for their cooperation during data collection. We wish to express our deep gratitude to the Director, Anthropological Survey of India, for his kind permission to initiate the work and also for providing financial support. We are also thankful to the Head of Office, Anthropological Survey of India, Western Regional Centre, Udaipur for providing all the logistic support.

## 8. Reference

- [1] Buckalew VM Jr, Berg RL, Wang SR, et al. Prevalence of hypertension in 1,795 subjects with chronic renal disease: The modification of diet in renal disease study baseline cohort: Modification of Diet in Renal Disease Study Group. *Am J Kidney Dis* 1996; 28:811–821.
- [2] Perry HM Jr, Miller JP, Fornoff JR, et al. Early predictors of 15-year end-stage renal disease in hypertensive patients. *Hypertension* 1995; 25:587–594.
- [3] Klag MJ, Whelton PK, Randall BL, et al. Blood pressure and end stage renal disease in men. *N Engl J Med* 1996; 334:13–18.
- [4] Brazy P C, Stead WW, Fitzwilliam J F. Progression of renal insufficiency: Role of blood pressure. *Kidney Int* 1989; 35:670–674.
- [5] Locatelli F, Marcelli D, Comelli M, et al. Proteinuria and blood pressure as causal components of progression to end-stage renal failure: Northern Italian Cooperative Study Group. *Nephrol Dial Transplant* 1996; 11:461–467.
- [6] Corvol P, Soubrier F, Jeunemaitre X. Molecular genetics of the renin-angiotensin-aldosterone system in human hypertension. *Pathol Biol (Paris)* 1997; 45:229–239.
- [7] Wakahara S, Konoshita T, Mizuno S, Motomura M, Aoyama C, Makino Y, Kato N, Koni I, Miyamori I. Synergistic expression of angiotensin-converting enzyme (ACE) and ACE2 in human renal tissue and confounding effects of hypertension on the ACE to ACE2 ratio. *Endocrinology* 2007; 148:2453–2457.
- [8] Konoshita T, Wakahara S, Mizuno S, Motomura M, Aoyama C, Makino Y, et al. Tissue gene expression of renin - angiotensin system in human type 2 diabetic nephropathy. *Diabetes Care* 2006; 29:848–852.
- [9] Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G. Effects of an angiotensin converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. *N Engl J Med* 2000; 342:145–153.



- [10] Kjeldsen SE, Dahlof B, Devereux RB, Julius S, Aurup P et al. Effects of losartan on cardiovascular morbidity and mortality in patients with isolated systolic hypertension and left ventricular hypertrophy: a Losartan Intervention for Endpoint Reduction (LIFE) substudy. *JAMA* 2002; 288:1491-1498.
- [11] NAVIGATOR Study Group, McMurray JJ, Holman RR, Haffner SM, Bethel MA, et al. Effect of valsartan on the incidence of diabetes and cardiovascular events. *N Engl J Med* 2010; 362:1477-1490.
- [12] Miller S.A., Dykes D.D., Polesky H.F. A simple salting out procedure for extracting DNA from human nucleated cells. *Nucleic Acid Res* 1988; 16:12-15.
- [13] Nakajima T, Lynn B, Jorde, Tomoaki Ishigami, Satoshi Umemura, Missuru Emi et al. Nucleotide Diversity and Haplotype Structure of the Human Angiotensinogen Gene in Two Populations. *Am. J. Hum. Genet* 2002; 70:108-123.
- [14] Deinum J, Lise Tornow, Jeanette M. van Gool, Rene A. de Bruin et al. Plasma renin and prorenin and renin gene variation in patients with insulin-dependent diabetes mellitus and nephropathy. *Nephrol Dial Transplant* 1999; 14: 1904-1911.
- [15] Rigat, B., Hubert, C., Corvol, P., Soubrier, F. PCR detection of the insertion/deletion polymorphism of the human Angiotensin converting enzyme gene (DCP1) (dipeptidylcarboxypeptidase 1). *Nucleic Acid Research* 1992; 20:1433.
- [16] Prasad P, Tiwari A K, Kumar KM P, Ammini AC, Gupta A et al. Chronic renal insufficiency among Asian Indians with type 2 diabetes: I. Role of RAAS gene polymorphisms. *BMC Medical Genetics* 2006; 7(42): 1471-2350.
- [17] Jiang Xiao, Sheng Hai-hui, Lin Gang, Li Jian, Lu Xin-zheng, et al. Effect of renin - angiotensin- aldosterone system gene polymorphisms on blood pressure response to antihypertensive treatment, *Chin Med J* 2007; 120(9): 782 - 786.
- [18] PLINK (<http://pngu.mgh.harvard.edu/~purcell/plink/>).
- [19] Jackson AE, Cassell PG, North BV, Vijayaraghavan S, Gelding SV, et al. Polymorphic variations in the neurogenic differentiation-1, neuregenin 3, and hepatocyte nuclear factor-1 $\alpha$  genes contribute to glucose intolerance in south Indian population. *Diabetes* 2004; 53:2111-2125.
- [20] Guettier J-M, Georgopoulos A, Tsai MY, Radha V, Shanthirani S, et al. Polymorphisms in the fatty acid-binding protein 2 and apolipoprotein C-III genes are associated with the metabolic syndrome and dyslipidemia in a south Indian population. *J Clin Endocrinol Metab* 2005; 90:1705-1711.
- [21] Abate N, Chandalia M, Satija P, Adams-Huet B, Grundy SM, et al. ENPP1/PC-1 K121Q polymorphism and genetic susceptibility to type 2 diabetes. *Diabetes* 2005; 54:1207-1213.
- [22] Rai E, Sharma S, Koul A, Bhat AK, Bhanwer AJ, Bamezai RN. Interaction between the UCP2-866G/A, mtDNA 10398G/A and PGC1 $\alpha$  p.Thr394Thr and p.Gly482Ser polymorphisms in type 2 diabetes susceptibility in North Indian population. *Hum Genet* 2007 ; 122:535-540.
- [23] Chandak GR, Janipalli CS, Bhaskar S, Kulkarni SR, Mohankrishna P, et al. Common variants in the TCF7L2 gene are strongly associated with type 2 diabetes mellitus in the Indian population. *Diabetologia* 2007; 50:63-7.
- [24] Bodhini D, Radha V, Dhar M, Narayani N, Mohan V. The rs12255372 (G/T) and rs7903146 (C/T) polymorphisms of the TCF7L2 gene are associated with type 2 diabetes mellitus in Asian Indians. *Metabolism* 2007; 56(9):1174-8.
- [25] Jeunemaitre X, Soubrier F, Kotelevtsev YV, Lifton RP, Williams CS, et al. Molecular basis of human hypertension: Role of angiotensinogen. *Cell* 1992; 71:169-180.
- [26] Forrester T, McFarlane-Anderson N, Bannet F, Wilks R, Puras A, et al. Angiotensinogen and blood pressure among blacks: findings from a community survey in Jamaica. *J Hypertens* 1996; 14: 315-317.
- [27] Rotimi C, Morrison L, Cooper R, Oyejide C, Effiong E, Ladipo M. Angiotensinogen gene in human hypertension: lack of an association of the 235T allele among African Americans. *Hypertension* 1994; 24:591-594.
- [28] Agachan B, Isbir T, Yilmaz H, Akoglu E. Angiotensin converting enzyme I/D, angiotensinogen T174M-M235T and angiotensin II type 1 receptor A1166C gene polymorphisms in Turkish hypertensive patients. *Exp Mol Med* 2003; 35(6): 545-549.
- [29] Jia En-Zhi, Zhen-Xia Xu, Chang-Yan Guo, Li Li, Yan Gu, et al. Renin-Angiotensin-Aldosterone System Gene Polymorphisms and Coronary Artery Disease: Detection of Gene-Gene and Gene-Environment Interactions. *Cell Physiol Biochem* 2012; 29:443-452.
- [30] Mtiraoui Nabil, Intissar Ezzidi, Amira Turki, Molka Chaieb, Touhami Mahjoub and Wassim Y Almawi. Renin -angiotensin-aldosterone system genotypes and haplotypes affect the susceptibility to nephropathy in type 2 diabetes patients. *J of Renin-Angiotensin-Aldosterone Syst* 2011; 12(4): 572-580.
- [31] Abbud ZA, Wilson AC, Cosgrove NM, Kostis JB. Angiotensin- converting enzyme gene polymorphism in systemic hypertension. *Am J Cardiol* 1998; 81:244-246.
- [32] Bedir A, Arik N, Adam B, Kilinc K, Gumus T and Guner E. Angiotensin converting enzyme gene polymorphism and activity in Turkish patients with essential hypertension. *Am J Hypertens* 1999; 12: 1038-43.
- [33] O'Donnell CJ, Lindpaintner K, Larson MG, Rao VS, Ordovas JM, Schaefer EJ, et al. Evidence for association and genetic linkage of the angiotensin-converting enzyme locus with hypertension and blood pressure in men but not women in the Framingham Heart Study. *Circulation* 1998; 97:1766-1772.
- [34] Sikdar M, Purkait P, Raychoudhury P, Bhattacharya S K, Naidu JM and Sarkar BN. ACE Gene Insertion/Deletion Polymorphism and Type-2 Diabetic Nephropathy in Eastern Indian Population. *Human Biology Review* 2013; 2 (1): 66-76.
- [35] Bonardeaux A, Davies E, Jeunemaitre X, Fery I, Charru A, Clauser E, Tiret L, et al. Angiotensin II type 1 receptor gene polymorphisms in human essential hypertension. *Hypertension* 1994; 24:63-69.
- [36] Bassett MH, Zhang Y, Clyne C, et al. Differential regulation of aldosterone synthase and 11 beta-hydroxylase transcription by steroidogenic factor-1. *J Mol Endocrinol* 2002; 28: 125-35.
- [37] Russo P, Siani A, Venezia A, et al. Interaction between the C(-344)T polymorphism of CYP11B2 and age in the regulation of blood pressure and plasma aldosterone levels: cross-sectional and longitudinal findings of the Olivetti Prospective Heart Study. *J Hypertens* 2002; 20:1785-1792.
- [38] Keavney B, Mayosi B, Gaukrodger N et al. Genetic variation at the locus encompassing 11 - beta hydroxylase and aldosterone synthase accounts for heritability in cortisol precursor (11-deoxycortisol) urinary metabolite excretion. *J clin Endocrinol Metab* 2005; 90: 1072-7.
- [39] White PC, Slutsker I. Haplotype analysis of CYP11B2. *Endocr Res* 1995; 21:437-42.
- [40] Davies E, Holloway CD, Ingram MC, et al. Aldosterone excretion rate and blood pressure in essential hypertension are related to polymorphic differences in the aldosterone synthase gene CYP11B2. *Hypertension* 1999; 33:703-707.
- [41] Kumar NN, Benjafeld AV, Lin RC, et al. Haplotype analysis of aldosterone synthase gene (CYP11B2) polymorphisms shows association with essential hypertension. *J Hypertens* 2003; 21:1331-1337.
- [42] Brand E, Chatelain N, Mulatero P, et al. Structural analysis and evaluation of the aldosterone synthase gene in hypertension. *Hypertension* 1998; 32:198-204.
- [43] Tamaki S, Iwai N, Tsujita Y, et al. Genetic polymorphism of CYP11B2 gene and hypertension in Japanese. *Hypertension* 1999; 33:266-270.
- [44] Song J, Narita I, Goto S, et al. Gender specific association of aldosterone synthase gene polymorphism with renal survival in patients with IgA nephropathy. *J Med Genet* 2003; 40(5):372-6.
- [45] Lovati E, Richard A, Frey BM, et al. Genetic polymorphisms of the renin-angiotensin-aldosterone system in end-stage renal disease. *Kidney Int* 2001; 60:46-54.

- [46] Fabris B, Bortoletto M, Candido R, et al. Genetic polymorphisms of the renin-angiotensin-aldosterone system and renal insufficiency in essential hypertension. *J Hypertens* 2005; 23:309-316.
- [47] Lee Ji Eun, So Yon Bae, Jeong-Yup Kim, et al. Aldosterone Synthase Gene (CYP11B2) Polymorphism in Korean End-Stage Renal Disease Patients on Hemodialysis. *Electrolytes Blood Press* 2009; 7:67-72.
- [48] Rajan S., Ramu P., Shewade D.G., Adithan C, Promoter region polymorphism of CYP11B2 (344 C>T) gene in healthy volunteers of South Indian TAMILIAN population. *Indian Journal Biotech* 2009; 8: 358-362.
- [49] Rajput C, Makhijani K, Norboo T, et al. CYP11B2 gene polymorphisms and hypertension in highlanders accustomed to high salt intake. *J Hypertens* 2005; 23 : 79-86.
- [50] Rajan S., P. Ramu, G. Umamaheswaran et al. Association of aldosterone synthase (CYP11B2 C-344T) gene polymorphism & susceptibility to essential hypertension in a south Indian Tamil population, *Indian J Med Res* 2010; 132: 379-385.
- [51] Pulakes Purkait, B.N. Sarkar and J.M. Naidu. Null association of aldosterone synthase (cyp11b2) gene-344 C > T promoter polymorphism in type 2 diabetic patients among Indian population. (Abstract). *J Diabetes Metab* 2012; 3:8.